| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026293422 |
| P356 | DOI | 10.1038/BJC.2011.118 |
| P932 | PMC publication ID | 3093360 |
| P698 | PubMed publication ID | 21468051 |
| P5875 | ResearchGate publication ID | 51020607 |
| P50 | author | Rosalind Eeles | Q24640445 |
| Nora Pashayan | Q55174850 | ||
| Douglas F. Easton | Q59812154 | ||
| Paul D P Pharoah | Q61822938 | ||
| David E. Neal | Q42941105 | ||
| P2093 | author name string | T Dent | |
| H Burton | |||
| S Chowdhury | |||
| S W Duffy | |||
| P2860 | cites work | Mortality results from a randomized prostate-cancer screening trial | Q24601536 |
| Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England | Q24629668 | ||
| A common variant associated with prostate cancer in European and African populations | Q46921392 | ||
| Multiple loci on 8q24 associated with prostate cancer susceptibility. | Q50582715 | ||
| [Detection of cancer, sensitivity of the test and sensitivity of the screening program] | Q52417483 | ||
| Two variants on chromosome 17 confer prostate cancer risk and the one in TCF2 protects against type 2 diabetes | Q56968912 | ||
| A common coding variant in CASP8 is associated with breast cancer risk | Q57250674 | ||
| Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer | Q57251792 | ||
| Screening younger women with a family history of breast cancer – does early detection improve outcome? | Q57266725 | ||
| Polygenic susceptibility to breast cancer and implications for prevention | Q78029012 | ||
| Cumulative association of five genetic variants with prostate cancer | Q80503113 | ||
| Polygenes, risk prediction, and targeted prevention of breast cancer | Q81523323 | ||
| A tiny step closer to personalized risk prediction for breast cancer | Q83201462 | ||
| Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease | Q84183538 | ||
| Genome-wide association study identifies novel breast cancer susceptibility loci | Q24645441 | ||
| Prostate-specific antigen testing accuracy in community practice | Q24799377 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Multiple newly identified loci associated with prostate cancer susceptibility | Q28268180 | ||
| Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer | Q28943505 | ||
| Multiple loci identified in a genome-wide association study of prostate cancer | Q28943507 | ||
| Identification of seven new prostate cancer susceptibility loci through a genome-wide association study | Q29417022 | ||
| Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 | Q29614925 | ||
| Screening and prostate-cancer mortality in a randomized European study | Q29617485 | ||
| Clinical utility of five genetic variants for predicting prostate cancer risk and mortality | Q30492173 | ||
| Breast cancer in young women: poor survival despite intensive treatment | Q30882889 | ||
| Association of prostate cancer risk variants with clinicopathologic characteristics of the disease | Q33606941 | ||
| Genome-wide association studies in cancer--current and future directions | Q33814805 | ||
| Performance of common genetic variants in breast-cancer risk models | Q34064069 | ||
| A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). | Q34085748 | ||
| Genome-wide association study identifies five new breast cancer susceptibility loci | Q34114293 | ||
| Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study | Q34168865 | ||
| Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer | Q34631785 | ||
| Age-conditional probabilities of developing cancer | Q34667627 | ||
| Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12 | Q35282592 | ||
| Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients | Q35749359 | ||
| Maximising benefit and minimising harm of screening | Q36482925 | ||
| Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility | Q36582802 | ||
| Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk | Q36858843 | ||
| Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening | Q37160706 | ||
| Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. | Q37300024 | ||
| FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation | Q37323340 | ||
| Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. | Q37356243 | ||
| Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. | Q37369631 | ||
| Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? | Q44096816 | ||
| Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening | Q44739181 | ||
| Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. | Q46332214 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| prostate cancer | Q181257 | ||
| P304 | page(s) | 1656-1663 | |
| P577 | publication date | 2011-04-05 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Polygenic susceptibility to prostate and breast cancer: implications for personalised screening | |
| P478 | volume | 104 |
| Q39167311 | "It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer |
| Q93103805 | A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density |
| Q35177444 | A genome-wide pleiotropy scan for prostate cancer risk |
| Q34472668 | Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium |
| Q35592936 | Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. |
| Q43903120 | Advanced stage diagnosis of cancer: who is at greater risk? |
| Q92402303 | Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study |
| Q35086233 | An epidemiological perspective of personalized medicine: the Estonian experience |
| Q42363834 | Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers |
| Q87909686 | Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening |
| Q30238753 | Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. |
| Q36393193 | Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement |
| Q36481548 | Breast cancer risk prediction and mammography biopsy decisions: a model-based study |
| Q43128186 | Breast cancer screening: time to target women at risk |
| Q35834376 | Can the breast screening appointment be used to provide risk assessment and prevention advice? |
| Q91211233 | Cancer genetics, precision prevention and a call to action |
| Q34661857 | Characterization of SNPs associated with prostate cancer in men of Ashkenazic descent from the set of GWAS identified SNPs: impact of cancer family history and cumulative SNP risk prediction |
| Q35868793 | Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) |
| Q36387040 | Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy |
| Q40208005 | Comparison of the efficiency of colorectal cancer screening programs based on age and genetic risk for reduction of colorectal cancer mortality. |
| Q38435623 | Comprehensive evaluation of the impact of 14 genetic variants on colorectal cancer phenotype and risk |
| Q31064480 | Constructing Hypothetical Risk Data from the Area under the ROC Curve: Modelling Distributions of Polygenic Risk |
| Q89561075 | Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential |
| Q57177092 | Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model |
| Q40096570 | Cumulative risk of cancer detection in breast cancer screening by protocol strategy |
| Q28084601 | Do Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling? |
| Q42268071 | Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis. |
| Q35917987 | End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine |
| Q30854346 | Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer |
| Q89966674 | Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities |
| Q89737634 | External validation of a mammographic texture marker for breast cancer risk in a case-control study |
| Q36053127 | Genetic architecture of colorectal cancer |
| Q33901182 | Genetic control of ductal morphology, estrogen-induced ductal growth, and gene expression in female mouse mammary gland |
| Q43415543 | Genetic variants associated with predisposition to prostate cancer and potential clinical implications |
| Q47900293 | Genome-wide association studies of cancer: current insights and future perspectives |
| Q85278355 | Genomic medicine: challenges and opportunities for physicians |
| Q33356511 | Hereditary breast cancer: ever more pieces to the polygenic puzzle |
| Q35885086 | Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma |
| Q26825771 | Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issues |
| Q40310422 | Implications of polygenic risk for personalised colorectal cancer screening |
| Q35602297 | Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis |
| Q37614763 | Incorporating genomics into breast and prostate cancer screening: assessing the implications |
| Q36763159 | Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges. |
| Q39094483 | Is mammography screening history a predictor of future breast cancer risk? |
| Q42343135 | Life insurance: genomic stratification and risk classification |
| Q64945839 | Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models. |
| Q96604435 | Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations |
| Q37463923 | Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors. |
| Q37181547 | Molecular genetics of breast and ovarian cancer: recent advances and clinical implications |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q92006924 | Personalized breast cancer screening strategies: A systematic review and quality assessment |
| Q37333975 | Personalized screening for cancers: should we consider polygenic profiling? |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q47561710 | Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts |
| Q37513339 | Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps |
| Q36233914 | Population-based screening in the era of genomics |
| Q36097440 | Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers |
| Q38820915 | Precisely Where Are We Going? Charting the New Terrain of Precision Prevention. |
| Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q37223335 | Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status |
| Q36229139 | Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda |
| Q38177161 | Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments |
| Q34811135 | Public health genomics and personalized prevention: lessons from the COGS project |
| Q86499074 | Public health implications from COGS and potential for risk stratification and screening |
| Q41728154 | Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer |
| Q37524981 | Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies |
| Q36295073 | Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. |
| Q54257615 | Research Highlights: New insights into prostate cancer susceptibility. |
| Q35815958 | Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci |
| Q39289771 | Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms |
| Q39044222 | Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine. |
| Q46953427 | Strategies for developing prediction models from genome-wide association studies |
| Q59073013 | Summary of the Evidence of Breast Cancer Service Screening Outcomes in Europe and First Estimate of the Benefit and Harm Balance Sheet |
| Q47901606 | Summary statement on screening for prostate cancer in Europe |
| Q36190584 | Targeted Cancer Screening in Average-Risk Individuals |
| Q47161591 | The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol. |
| Q92282029 | The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches |
| Q38168060 | The genetic epidemiology of prostate cancer and its clinical implications |
| Q27025062 | The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making |
| Q36294980 | Twenty-five years of breast cancer risk models and their applications |
| Q35922603 | Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women. |
| Q92755500 | Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management |
| Q91594655 | Willingness to decrease mammogram frequency among women at low risk for hereditary breast cancer |
Search more.